Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Go back to Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Novo Nordisk earnings preview: Barclays and BofA weigh in

November 4, 2025 4:00 PM EST

Barclays and Bank of America both expect Novo Nordisk's (NYSE: NVO) third-quarter results on November 5 to come broadly in line with expectations but warn the drugmaker could lower the upper end of its 2025 guidance as prescription trends soften.

Barclays analyst Yihan Li said the bank now models +10.9% FY25 topline CER growth (generally in-line with guidance... More